Novella Clinical has announced the acquisition of the leading full service Clinical Research Organization (CRO), Prologue Research International, Inc. Both companies focus on biotechnology, pharmaceutical and medical device technology, though Prologue has an emphasis in oncology drug development. The acquisition will improve Novella’s standing as leader in oncology therapy and drug development. Details of the acquisition have not been released.

“The acquisition of Prologue strengthens our oncology therapeutic franchise and is a strategic addition to our earlier announced deal this year with OSI Pharmaceuticals,” says Richard Staub, President and Chief Executive Officer in a statement. “Prologue’s experience includes the management of more than 120 oncology trials across a wide variety of indications with a customer base that does not overlap with Novella Clinical’s. With Prologue, Novella will expand its support to oncology Sponsors with the creation of a dedicated business unit focused exclusively on oncology drug development, with the objective of bringing much needed products to market to improve the lives of people with cancer.”

“We are excited to be joining forces with Novella Clinical. Combining Prologue’s experienced oncology team with Novella Clinical’s oncology team, their infrastructure and e-based technology allows us to better serve current and future customers in the design and execution of complex oncology programs across geographic regions,” said Tom Ludlam, President and CEO of Prologue.

Novella Clinical will add 60 staff to their existing staff of 738 professionals in addition to an office in Columbus, Ohio, where Prologue Research International is based.

Source: Novella Clinical